Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1116-1117, 2004; 10.1373/clinchem.2004.034645
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baynes, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baynes, J. W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Current Issues in Laboratory Medicine
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2004;50:1116-1117.)
© 2004 American Association for Clinical Chemistry, Inc.

Editorial

The Clinical Chemome: A Tool for the Diagnosis and Management of Chronic Disease

John W. Baynes

Department of Chemistry and Biochemistry, Graduate Sciences Research Center, University of South Carolina, Columbia, SC 29208, Fax 803-777-7272

E-mail john.baynes@sc.edu

The first 20% of the full text of this article appears below.

Garrod was among the first to recognize the importance of genetics as a determinant of disease. In his Croonian Lecture in 1908, he introduced the term "inborn errors of metabolism", long before the nature of genes, proteins, and enzymes was understood. Numerous recent articles in Clinical Chemistry have focused on the application of modern mass spectrometry to the analysis of metabolites in plasma or urine for diagnosis of genetic diseases resulting from defects in single enzymes or transport systems. Novel liquid chromatography–mass spectrometry (LC/MS) methodologies, supported by bioinformatics and pattern-recognition algorithms, are also being developed for "omic" analysis and diagnosis of disease, including "genomics" (genetic complement), "transcriptomics" (gene expression), "proteomics" (protein synthesis and signaling), "metabolomics" (concentrations and fluxes of cellular metabolites), and "metabonomics" (systemic profiling by analysis of biological fluids) (1).

The more common, noninfectious diseases in the modern world, such as cancer, diabetes, and cardiovascular and neurodegenerative diseases, do not fit into Garrod’s construct—that a deficiency in a single enzyme leads to a single disease entity. These and other chronic, age-related diseases are multifactorial and multigene in origin and often have a substantial nonenzymatic, nonmetabolic, chemical component. Chemical modification of proteins, often as a result of oxidative stress mediated by reactive oxygen and nitrogen species, . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.